These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 527209)

  • 41. Active transport of methotrexate from cerebrospinal fluid in humans.
    Bode U; Magrath IT; Bleyer WA; Poplack DG; Glaubiger DL
    Cancer Res; 1980 Jul; 40(7):2184-7. PubMed ID: 7388786
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
    Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
    Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors. 15 years of experience.
    Garrett AP; Garner EO; Goldstein DP; Berkowitz RS
    J Reprod Med; 2002 May; 47(5):355-62. PubMed ID: 12063874
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions.
    Howell SB; Chu BB; Wung WE; Metha BM; Mendelsohn J
    J Clin Invest; 1981 Apr; 67(4):1161-70. PubMed ID: 6970753
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adjuvant methotrexate in the radiotherapeutic management of advanced tumors of the head and neck.
    Lustig RA; DeMare PA; Kramer S
    Cancer; 1976 Jun; 37(6):2703-8. PubMed ID: 949688
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
    Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
    Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-dose methotrexate with a safe rescue program.
    Decker DA; Edmonson JH; Gilchrist GS; Kovach JS; Offord JR; Taylor WF
    Oncology; 1981; 38(5):262-4. PubMed ID: 6973732
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Methotrexate and 5-fluorouracil in head and neck cancer.
    Ringborg U; Ewert G; Kinnman J; Lundquist PG; Strander H
    Semin Oncol; 1983 Jun; 10(2 Suppl 2):20-2. PubMed ID: 6603022
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution.
    Zhang W; Zhang Q; Tian X; Zhao H; Lu W; Zhen J; Niu X
    Chin Med J (Engl); 2015 Jan; 128(1):111-8. PubMed ID: 25563323
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systemic high-dose intravenous methotrexate for central nervous system metastases.
    Lassman AB; Abrey LE; Shah GD; Panageas KS; Begemann M; Malkin MG; Raizer JJ
    J Neurooncol; 2006 Jul; 78(3):255-60. PubMed ID: 16344918
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adjuvant methotrexate escalated to toxicity for resectable stage III and IV squamous head and neck carcinomas--a prospective, randomized study.
    Rentschler RE; Wilbur DW; Petti GH; Chonkich GD; Hilliard DA; Camacho ES; Thorpe RB
    J Clin Oncol; 1987 Feb; 5(2):278-85. PubMed ID: 3806169
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Individual dose adjustment of high-dose methotrexate in clinical practice].
    Bagarry-Liégey D; Nicoara A; Duffaud F; Guillet P; Pignon T; Catalin J; Durand A; Favre R
    Rev Med Interne; 1996; 17(8):689-98. PubMed ID: 8881200
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Pharmacokinetics of methotrexate and therapeutic drug monitoring in children with osteosarcoma. Computer simulation using a pharmacokinetic model].
    Piekarczyk A; Zimak J; Taljański W
    Med Wieku Rozwoj; 2000; 4(2 Suppl 2):27-33. PubMed ID: 11178326
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.
    Cipriani P; Ruscitti P; Carubbi F; Liakouli V; Giacomelli R
    Clin Ther; 2014 Mar; 36(3):427-35. PubMed ID: 24612941
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck.
    Hong WK; Schaefer S; Issell B; Cummings C; Luedke D; Bromer R; Fofonoff S; D'Aoust J; Shapshay S; Welch J; Levin E; Vincent M; Vaughan C; Strong S
    Cancer; 1983 Jul; 52(2):206-10. PubMed ID: 6190545
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current studies of methotrexate and 5-fluorouracil and their interaction in human tumor cells.
    Tattersall MH
    Semin Oncol; 1983 Jun; 10(2 Suppl 2):6-14. PubMed ID: 6867755
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advantages and limitations of pharmacokinetic studies in the rationalization of anticancer therapy: methotrexate and 5-FU.
    Cano JP; Aubert C; Rigault JP; Gilli R; Coassolo P; Monjanel S; Seitz JF; Carcassone Y
    Cancer Treat Rep; 1981; 65 Suppl 3():33-42. PubMed ID: 7346155
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Methotrexate with thymidine, inosine, and allopurinol rescue: a phase I clinical study.
    Dady PJ; Taylor GA; Muindi JF; Calvert AH; Smith IE; Smyth JF; Harrap KR
    Cancer Treat Rep; 1981; 65 Suppl 1():37-43. PubMed ID: 7326664
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Initial adjuvant therapy in advanced squamous cell carcinoma of the head and neck employing weekly high dose methotrexate with leucovorin rescue.
    Pitman SW; Miller D; Weichselbaum R
    Laryngoscope; 1978 Apr; 88(4):632-8. PubMed ID: 306011
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Methotrexate/fluorouracil scheduling influences normal tissue toxicity but not antitumor effects in patients with squamous cell head and neck cancer: results from a randomized trial.
    Browman GP; Levine MN; Goodyear MD; Russell R; Archibald SD; Jackson BS; Young JE; Basrur V; Johanson C
    J Clin Oncol; 1988 Jun; 6(6):963-8. PubMed ID: 3286831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.